View ValuationDigicann Ventures 将来の成長Future 基準チェック /06現在、 Digicann Venturesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長23.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Dec 02Digicann Ventures Inc. Appoints Jordan Fogle as A Director, Effective December 2, 2025Digicann Ventures Inc. announced the appointment of Jordan Fogle as a director of the Company. Jordan's appointment as a member of the board of directors (the "Board") is effective on December 2, 2025 and is subject to all applicable regulatory approvals.お知らせ • Oct 303WIN Corp. cancelled the acquisition of Digicann Ventures Inc. (CNSX:DCNN) in a reverse merger transaction.3WIN Corp. entered into a letter of intent to acquire Digicann Ventures Inc. (CNSX:DCNN) in a reverse merger transaction for CAD 39.7 million on August 1, 2024. On September 27, 2024, Digicann Ventures entered into a Definitive Agreement for Proposed RTO Transaction with 3Win Corp. Pursuant to the terms of the LOI, the holders of Digicann Shares shall receive a deemed value of CAD 0.05 per share and, upon completion of the Proposed Transaction, 3Win Corp. expects to affect a name change to “Serewin Inc.”. A sub-committee of Digicann’s board of directors (excluding Mr. Kuzyk) determined that the Agreement, including the transactions and other steps contemplated thereunder, is fair to holders of Digicann securities and is in the best interests of the Company. As of January 13, 2025 3Win has elected to postpone the Proposed Transaction to the second quarter of 2025 in order to include its 2024 audited financial results in the disclosures required for listing on the Canadian Securities Exchange. Accordingly, Digicann’s board of directors approved the Agreement and recommends that holders vote their shares in favour of the Proposed Transaction. Completion of the Proposed Transaction is subject to a number of conditions precedent, including but not limited to, the parties entering into a Definitive Agreement, Digicann having a minimum amount of cash at closing of the Proposed Transaction, as well as receipt of all required shareholder, regulatory, and other approvals. Pursuant to the terms of the Definitive Agreement, 3Win shall acquire all the shares of the Company, in the exchange ratio of ninety-eight shares of the Company per one share of 3Win. Upon completion of the Proposed Transaction, the resulting holders of all issued and outstanding shares of 3Win (“3Win Shares”) shall hold approximately 97.3% of the issued and outstanding common shares of the Resulting Issuer (the “Exchange Ratio”), subject to adjustment in certain circumstances and for any additional amounts invested by third parties into 3Win to satisfy any liquidity conditions imposed by the Exchange in connection with the Proposed Transaction. It is also anticipated that all securities convertible, exercisable or exchangeable for 3Win Shares will be converted or exchange (or otherwise become convertible or exercisable in accordance with their terms) into similar securities of the Resulting Issuer on substantially similar terms and conditions based on the Exchange Ratio. All outstanding stock options and common share purchase warrants of the Company are anticipated to remain in effect on substantially the same terms. 3WIN Corp. cancelled the acquisition of Digicann Ventures Inc. (CNSX:DCNN) in a reverse merger transaction on October 29, 2025.お知らせ • Mar 12Digicann Ventures Inc. announced a financing transactionDigicann Ventures Inc. announced that it has entered into an agreement with the holders of the company to issue 10% Senior Unsecured Convertible Debentures to receive funding on March 12, 2025. The maturity date of the debentures is March 12, 2026.お知らせ • Aug 043WIN Corp. entered into a letter of intent to acquire Digicann Ventures Inc. (CNSX:DCNN) for CAD 0.22 million.3WIN Corp. entered into a letter of intent to acquire Digicann Ventures Inc. (CNSX:DCNN) for CAD 0.22 million on August 1, 2024. Pursuant to the terms of the LOI, the holders of Digicann Shares shall receive a deemed value of CAD 0.05 per share and, upon completion of the Proposed Transaction3Win Corp. expects to affect a name change to “Serewin Inc.”. Completion of the Proposed Transaction is subject to a number of conditions precedent, including but not limited to, the parties entering into a Definitive Agreement, Digicann having a minimum amount of cash at closing of the Proposed Transaction, as well as receipt of all required shareholder, regulatory, and other approvals.Buy Or Sell Opportunity • Mar 29Now 63% undervaluedThe stock has been flat over the last 90 days, currently trading at €0.0065. The fair value is estimated to be €0.018, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 34% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Feb 24Now 86% undervaluedThe stock has been flat over the last 90 days, currently trading at €0.002. The fair value is estimated to be €0.014, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 34% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Feb 01Now 85% undervaluedThe stock has been flat over the last 90 days, currently trading at €0.0005. The fair value is estimated to be €0.0034, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 34% over the last 3 years. Meanwhile, the company became loss making.お知らせ • Jun 08Agra Ventures Ltd. Appoints Jonathan Hirsh as an Independent Member of the Board of DirectorsAgra Ventures Ltd. announced that Jonathan Hirsh has been appointed as an independent member of the Board of Directors . Best known for his influential work as @Weedstagram416 on the Instagram platform, Jonathan is a globally recognized figure in the cannabis industry, with multiple nominations for the Canadian Cannabis Awards, in both the Influencer of the Year and Cannabis Crusader categories. His impressive portfolio of partnerships comprises over 300 major cannabis-related brands. As a respected voice in the cannabis discourse, Jonathan has journeyed worldwide to judge international cannabis competitions and share his insights at various industry events. Notably, he was among only seven judges invited to participate in the esteemed Jack Herer Cup in Amsterdam. He has also been a guest speaker at CannEx Jamaica in Montego Bay. Jonathan's commitment to cannabis education led him to academia, where he served as a professor of cannabis history at Centennial College. Most recently, he was VP of Marketing and Consumer Experience for Mera Cannabis. There, Jonathan played a pivotal role in developing and launching one of Canada's first legal infused pre-rolls under the Avana and Countryside brands.お知らせ • Jun 03Agra Ventures Ltd., Annual General Meeting, Jul 21, 2023Agra Ventures Ltd., Annual General Meeting, Jul 21, 2023. Location: Suite 810 789 West Pender Street V6C 1H2 Vancouver British Columbia Canadaお知らせ • Jun 01Agra Ventures Ltd. (CNSX:AGRA) acquired Agraflora Europe Gmbh.Agra Ventures Ltd. (CNSX:AGRA) acquired Agraflora Europe Gmbh on March 31, 2023.Agra Ventures Ltd. (CNSX:AGRA) completed the acquisition of Agraflora Europe Gmbh on March 31, 2023.Board Change • Jul 21Less than half of directors are independentThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 new directors. 3 experienced directors. 4 highly experienced directors. 1 independent director (2 non-independent directors). Member of the Advisory Board C. Rebagliati is the most experienced director on the board, commencing their role in 2007. Independent Director Anthony Carnevale was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Board Change • Jun 30Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Brian O’Neill was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Jun 04First quarter 2022 earnings released: EPS: CA$0.10 (vs CA$0.29 in 1Q 2021)First quarter 2022 results: EPS: CA$0.10 (down from CA$0.29 in 1Q 2021). Net income: CA$1.42m (down 45% from 1Q 2021).Reported Earnings • May 04Full year 2021 earnings released: CA$0.43 loss per share (vs CA$11.79 loss in FY 2020)Full year 2021 results: CA$0.43 loss per share (up from CA$11.79 loss in FY 2020). Net loss: CA$5.10m (loss narrowed 95% from FY 2020).Reported Earnings • Nov 30Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: CA$0.03 loss per share (up from CA$0.50 loss in 3Q 2020). Net loss: CA$359.4k (loss narrowed 93% from 3Q 2020). Revenue was in line with analyst estimates.Reported Earnings • Sep 01Second quarter 2021 earnings released: CA$0.30 loss per share (vs CA$0.77 loss in 2Q 2020)Second quarter 2021 results: Net loss: CA$3.58m (loss narrowed 45% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.Reported Earnings • Jun 02First quarter 2021 earnings released: EPS CA$0.002 (vs CA$0.009 loss in 1Q 2020)First quarter 2021 results: Net income: CA$2.57m (up CA$11.8m from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 42% per year whereas the company’s share price has fallen by 47% per year.Reported Earnings • May 05Full year 2020 earnings released: CA$0.079 loss per share (vs CA$0.15 loss in FY 2019)Full year 2020 results: Net loss: CA$102.9m (loss widened 1.9% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 40% per year, which means it has not declined as severely as earnings. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Digicann Ventures は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:VY3 - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2025N/A000N/A9/30/2025N/A-100N/A6/30/2025N/A-100N/A3/31/2025N/A-100N/A12/31/2024N/A-100N/A9/30/2024N/A13-2-2N/A6/30/2024N/A13-2-2N/A3/31/2024N/A15-3-3N/A12/31/2023N/A15-3-3N/A9/30/20230-18-1-1N/A6/30/20230-19-1-1N/A3/31/20230-23-1-1N/A12/31/20220-20-1-1N/A9/30/20221033N/A6/30/20221122N/A3/31/20221-1-7-7N/A12/31/20211-1-6-6N/A9/30/20211-83-10-11N/A6/30/20211-88-10-10N/A3/31/20211-91-30N/A12/31/20201-103-10-5N/A9/30/20201-660-10N/A6/30/20201-98-20-11N/A3/31/20200-104-24-17N/A12/31/20190-101-18-14N/A9/30/2019N/A-57N/A-8N/A6/30/2019N/A-21N/A-9N/A3/31/2019N/A-10N/A-4N/A12/31/2018N/A-6N/A-3N/A9/30/2018N/A-6N/A-4N/A6/30/2018N/A-5N/A-2N/A3/31/2018N/A-4N/A-2N/A12/31/2017N/A-2N/A-2N/A9/30/2017N/A-2N/A-2N/A6/30/20170-3N/A-1N/A3/31/2017N/A-2N/A-1N/A12/31/20160-2N/A0N/A9/30/20160-1N/A0N/A6/30/20160-1N/A-1N/A3/31/20160-1N/A-1N/A12/31/20150-1N/A-1N/A9/30/20150-1N/A-1N/A6/30/20150-1N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: VY3の予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: VY3の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: VY3の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: VY3の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: VY3の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: VY3の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/27 23:41終値2026/05/27 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Digicann Ventures Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Siddharth RajeevFundamental Research Corp.
お知らせ • Dec 02Digicann Ventures Inc. Appoints Jordan Fogle as A Director, Effective December 2, 2025Digicann Ventures Inc. announced the appointment of Jordan Fogle as a director of the Company. Jordan's appointment as a member of the board of directors (the "Board") is effective on December 2, 2025 and is subject to all applicable regulatory approvals.
お知らせ • Oct 303WIN Corp. cancelled the acquisition of Digicann Ventures Inc. (CNSX:DCNN) in a reverse merger transaction.3WIN Corp. entered into a letter of intent to acquire Digicann Ventures Inc. (CNSX:DCNN) in a reverse merger transaction for CAD 39.7 million on August 1, 2024. On September 27, 2024, Digicann Ventures entered into a Definitive Agreement for Proposed RTO Transaction with 3Win Corp. Pursuant to the terms of the LOI, the holders of Digicann Shares shall receive a deemed value of CAD 0.05 per share and, upon completion of the Proposed Transaction, 3Win Corp. expects to affect a name change to “Serewin Inc.”. A sub-committee of Digicann’s board of directors (excluding Mr. Kuzyk) determined that the Agreement, including the transactions and other steps contemplated thereunder, is fair to holders of Digicann securities and is in the best interests of the Company. As of January 13, 2025 3Win has elected to postpone the Proposed Transaction to the second quarter of 2025 in order to include its 2024 audited financial results in the disclosures required for listing on the Canadian Securities Exchange. Accordingly, Digicann’s board of directors approved the Agreement and recommends that holders vote their shares in favour of the Proposed Transaction. Completion of the Proposed Transaction is subject to a number of conditions precedent, including but not limited to, the parties entering into a Definitive Agreement, Digicann having a minimum amount of cash at closing of the Proposed Transaction, as well as receipt of all required shareholder, regulatory, and other approvals. Pursuant to the terms of the Definitive Agreement, 3Win shall acquire all the shares of the Company, in the exchange ratio of ninety-eight shares of the Company per one share of 3Win. Upon completion of the Proposed Transaction, the resulting holders of all issued and outstanding shares of 3Win (“3Win Shares”) shall hold approximately 97.3% of the issued and outstanding common shares of the Resulting Issuer (the “Exchange Ratio”), subject to adjustment in certain circumstances and for any additional amounts invested by third parties into 3Win to satisfy any liquidity conditions imposed by the Exchange in connection with the Proposed Transaction. It is also anticipated that all securities convertible, exercisable or exchangeable for 3Win Shares will be converted or exchange (or otherwise become convertible or exercisable in accordance with their terms) into similar securities of the Resulting Issuer on substantially similar terms and conditions based on the Exchange Ratio. All outstanding stock options and common share purchase warrants of the Company are anticipated to remain in effect on substantially the same terms. 3WIN Corp. cancelled the acquisition of Digicann Ventures Inc. (CNSX:DCNN) in a reverse merger transaction on October 29, 2025.
お知らせ • Mar 12Digicann Ventures Inc. announced a financing transactionDigicann Ventures Inc. announced that it has entered into an agreement with the holders of the company to issue 10% Senior Unsecured Convertible Debentures to receive funding on March 12, 2025. The maturity date of the debentures is March 12, 2026.
お知らせ • Aug 043WIN Corp. entered into a letter of intent to acquire Digicann Ventures Inc. (CNSX:DCNN) for CAD 0.22 million.3WIN Corp. entered into a letter of intent to acquire Digicann Ventures Inc. (CNSX:DCNN) for CAD 0.22 million on August 1, 2024. Pursuant to the terms of the LOI, the holders of Digicann Shares shall receive a deemed value of CAD 0.05 per share and, upon completion of the Proposed Transaction3Win Corp. expects to affect a name change to “Serewin Inc.”. Completion of the Proposed Transaction is subject to a number of conditions precedent, including but not limited to, the parties entering into a Definitive Agreement, Digicann having a minimum amount of cash at closing of the Proposed Transaction, as well as receipt of all required shareholder, regulatory, and other approvals.
Buy Or Sell Opportunity • Mar 29Now 63% undervaluedThe stock has been flat over the last 90 days, currently trading at €0.0065. The fair value is estimated to be €0.018, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 34% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Feb 24Now 86% undervaluedThe stock has been flat over the last 90 days, currently trading at €0.002. The fair value is estimated to be €0.014, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 34% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Feb 01Now 85% undervaluedThe stock has been flat over the last 90 days, currently trading at €0.0005. The fair value is estimated to be €0.0034, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 34% over the last 3 years. Meanwhile, the company became loss making.
お知らせ • Jun 08Agra Ventures Ltd. Appoints Jonathan Hirsh as an Independent Member of the Board of DirectorsAgra Ventures Ltd. announced that Jonathan Hirsh has been appointed as an independent member of the Board of Directors . Best known for his influential work as @Weedstagram416 on the Instagram platform, Jonathan is a globally recognized figure in the cannabis industry, with multiple nominations for the Canadian Cannabis Awards, in both the Influencer of the Year and Cannabis Crusader categories. His impressive portfolio of partnerships comprises over 300 major cannabis-related brands. As a respected voice in the cannabis discourse, Jonathan has journeyed worldwide to judge international cannabis competitions and share his insights at various industry events. Notably, he was among only seven judges invited to participate in the esteemed Jack Herer Cup in Amsterdam. He has also been a guest speaker at CannEx Jamaica in Montego Bay. Jonathan's commitment to cannabis education led him to academia, where he served as a professor of cannabis history at Centennial College. Most recently, he was VP of Marketing and Consumer Experience for Mera Cannabis. There, Jonathan played a pivotal role in developing and launching one of Canada's first legal infused pre-rolls under the Avana and Countryside brands.
お知らせ • Jun 03Agra Ventures Ltd., Annual General Meeting, Jul 21, 2023Agra Ventures Ltd., Annual General Meeting, Jul 21, 2023. Location: Suite 810 789 West Pender Street V6C 1H2 Vancouver British Columbia Canada
お知らせ • Jun 01Agra Ventures Ltd. (CNSX:AGRA) acquired Agraflora Europe Gmbh.Agra Ventures Ltd. (CNSX:AGRA) acquired Agraflora Europe Gmbh on March 31, 2023.Agra Ventures Ltd. (CNSX:AGRA) completed the acquisition of Agraflora Europe Gmbh on March 31, 2023.
Board Change • Jul 21Less than half of directors are independentThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 new directors. 3 experienced directors. 4 highly experienced directors. 1 independent director (2 non-independent directors). Member of the Advisory Board C. Rebagliati is the most experienced director on the board, commencing their role in 2007. Independent Director Anthony Carnevale was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Board Change • Jun 30Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Brian O’Neill was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jun 04First quarter 2022 earnings released: EPS: CA$0.10 (vs CA$0.29 in 1Q 2021)First quarter 2022 results: EPS: CA$0.10 (down from CA$0.29 in 1Q 2021). Net income: CA$1.42m (down 45% from 1Q 2021).
Reported Earnings • May 04Full year 2021 earnings released: CA$0.43 loss per share (vs CA$11.79 loss in FY 2020)Full year 2021 results: CA$0.43 loss per share (up from CA$11.79 loss in FY 2020). Net loss: CA$5.10m (loss narrowed 95% from FY 2020).
Reported Earnings • Nov 30Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: CA$0.03 loss per share (up from CA$0.50 loss in 3Q 2020). Net loss: CA$359.4k (loss narrowed 93% from 3Q 2020). Revenue was in line with analyst estimates.
Reported Earnings • Sep 01Second quarter 2021 earnings released: CA$0.30 loss per share (vs CA$0.77 loss in 2Q 2020)Second quarter 2021 results: Net loss: CA$3.58m (loss narrowed 45% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Jun 02First quarter 2021 earnings released: EPS CA$0.002 (vs CA$0.009 loss in 1Q 2020)First quarter 2021 results: Net income: CA$2.57m (up CA$11.8m from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 42% per year whereas the company’s share price has fallen by 47% per year.
Reported Earnings • May 05Full year 2020 earnings released: CA$0.079 loss per share (vs CA$0.15 loss in FY 2019)Full year 2020 results: Net loss: CA$102.9m (loss widened 1.9% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 40% per year, which means it has not declined as severely as earnings.